Rivus raises $132m to advance clinical development of obesity treatment
Pharmaceutical Technology
SEPTEMBER 23, 2022
Rivus Pharmaceuticals has raised $132m in a Series B funding round to clinically advance its lead candidate, HU6, for the treatment of obesity and cardio-metabolic disorders.
Let's personalize your content